| Name | Sourcebio International |
|---|---|
| Epic | SBI |
| Isin | GB00BKSB1674 |
| Industry | Medical Equipment and Services |
| Latest share price | 115.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £85.31 | Debt ratio | n/a |
| Shares in issue | 74.18 | Debt-to-equity ratio | n/a |
| P/E ratio | 7.5 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 41.18 |
| Dividend cover | n/a | EPS growth | 14 |
| Earning per share | 22.5 | 52-week high / low | 97.50p / 170.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Sourcebio International |
|---|---|
| Address | 1 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire, United Kingdom, NG8 6PX |
| Telephone | +44 (0) 115 973 9012 |
| Website | http://www.sourcebioscience.com/ |
| Director | Position |
|---|---|
| Mr Christopher Mills | Non-Executive Director |
| Mr Marco Fumagalli | Non-Executive Director |
| Mr Jay LeCoque | Executive Chairman |
| Sir Ian James Carruthers | Senior Independent Non-Executive Director |
| Mr Simon Constantine | Independent Non-Executive Director |
| Mr Anthony James Ratcliffe | CFO and Company Secretary |
| Assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Reporting date | 31/12/21 | 31/12/20 | 31/12/19 |
| Intangible asssets and goodwill | 10.19 | 10.34 | 10.3 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 28.84 | 27.17 | 21.04 |
| Inventory / work in progress | 5 | 3.6 | 0.82 |
| Trade and other receivables | 7.24 | 10.47 | 5.23 |
| Cash and equivalents | 33.3 | 8.44 | 1.23 |
| Other current assets and asset held for resale | 0.78 | n/a | 0.47 |
| Total of all assets | 75.16 | 50.15 | 28.79 |
| Liabilities £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Short term liabilities | 14.43 | 6.18 | 30.5 |
| Long term liabilities | 12.42 | 12.14 | 75.54 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 26.85 | 18.32 | 106.04 |
| Net assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Net assets | 48.31 | 31.83 | -77.25 |
| Equity £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Share capital | 0.11 | 0.11 | 2.91 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 15.08 | -1.64 | -80.12 |
| Share premium account | 33.19 | 33.19 | n/a |
| Total equity | 48.31 | 31.83 | -77.25 |
| Income £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 21.11 | 10.7 | 1.03 |
| Pre-tax profit | 20.69 | 2.79 | -8.03 |